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ABSTRACT
Infanrix-IPV (GSK, Belgium) is a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus
combination vaccine (DTaP-IPV) licensed in many countries including Korea. In accordance with
Korean regulations, we conducted a post-marketing surveillance (PMS) to evaluate the safety of
DTaP-IPV administered to Korean children in routine immunization schedules. Children aged
<7 years receiving at least one dose of DTaP-IPV either as part of a primary (3-dose) vaccination
series or as a subsequent booster were enrolled. Adverse events (AEs), adverse drug reactions (ADRs)
and serious AEs (SAEs) were recorded after each dose during the 30-day post-vaccination follow-up
period. Among a total of 639 children, 289 subjects (45.2%) experienced AEs, mostly (79.2%)
assessed as being unlikely to be related to the vaccination. ADRs were reported in 13.0% of subjects.
Fever was the most commonly reported expected AE (11.9% of subjects) and also the most
commonly reported expected ADR (8.5% of subjects). No obvious association between AE incidence
and vaccine dose sequence was apparent. An unexpected AE was seen in 32.9% of children, and
unexpected ADRs were far less common (1.9%). Thirty-four SAEs were recorded in 26 subjects (4.1%),
in two of whom a causal association with the vaccine could not be excluded, although both
resolved quickly. Data from this PMS indicate that DTaP-IPV has an acceptable safety profile when
given to Korean children in accordance with local prescribing recommendations in routine child-
hood immunization. ClinicalTrials.gov identifier: NCT01568060
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Introduction
Globally, diphtheria, tetanus, pertussis (or whooping cough)
and polio cause significant morbidity and mortality particu-
larly amongst children.1 In Korea, childhood vaccinations
against diphtheria, tetanus, and pertussis (DTaP) and against
polio have been included in the National Immunization
Program (NIP) for over 30 years.2 Recommended immuniza-
tion schedules include giving DTaP as a three-dose primary
vaccination series in infants aged 2, 4 and 6 months, with
a fourth dose given at 15–18 months, and a fifth dose at
4–6 years of age.3 For polio, primary vaccination at age 2, 4
and 6 months is recommended, with a subsequent booster
dose at 4–6 years.3 High rates of vaccine uptake are reported;
surveillance data for 2012 report that for DTaP, 99.1% of
children completed primary vaccination, while 83.6% received
a fourth and 56.6% a fifth dose.4 In 2013, 99.6% of children
completed primary series of DTaP and 96.8% received
a fourth DTaP dose.5 For polio, reported vaccine uptake in
2012 was 98.3% and 73.0% for primary and booster vaccina-
tions, respectively.4
A combined diphtheria, tetanus, acellular pertussis and
inactivated poliovirus vaccine (DTaP-IPV, Infanrix-IPV,
GSK, Belgium) has been available for use in Korea since
2012.6 Infanrix-IPV is indicated for use in a three-dose pri-
mary schedule for immunization of infants aged 2 months
and older, against diphtheria, tetanus, pertussis and poliomye-
litis. DTaP-IPV is also indicated for use as the fifth dose of the
DTaP vaccine series and the fourth dose of the IPV series in
children aged 4–6 years.6 By reducing overall total number of
vaccine administrations and clinical visits, combination vac-
cines offer a number of advantages when implementing often
crowded childhood immunization schedules. Advantages
include greater flexibility and convenience, with potentially
improved vaccine uptake and reduced costs.7 Data from
a randomized controlled trial (RCT) conducted in Korean
infants indicate that DTaP-IPV has comparable immunogeni-
city and safety to that seen with separate DTaP and IPV
vaccinations when given as a three-dose primary vaccination
schedule.8 Studies conducted in other populations (including
the United States [US], Europe, and Australia) also indicate
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comparable immunogenicity and safety to separate DTaP and
IPV vaccinations when given a booster-dose. In addition, they
show DTaP-IPV can be safely co-administered with other
childhood vaccinations,9–15 and post-licensure surveillance
data from the US indicate no safety concerns.16
In accordance with regulations from the Ministry of Food
and Drug Safety (MFDS) in Korea,17 additional safety infor-
mation on the use of licensed vaccines in the Korean popula-
tion is required following vaccine registration.18,19 We
conducted a post-marketing surveillance (PMS) to evaluate
the safety of the DTaP-IPV vaccine when administered
according to the local prescribing information (PI) in children
in Korea (NCT01568060). The main objectives were to docu-
ment all adverse events (AEs) occurring during the 30-day
(day 0 to day 29) follow-up period after each vaccine dose,
including those with unestablished causal relationships to the
study vaccine (i.e., unexpected AEs), and all serious adverse
events (SAEs) occurring throughout the study (i.e., from
receiving the first dose of the vaccine until 30 days after
receiving the last vaccine dose). Those adverse events consid-
ered related to the study vaccine, or adverse drug reactions
(ADRs), and serious ADRs occurring during the surveillance
period were also documented.
Results
Study population
In total, 644 subjects were enrolled by 17 doctors in 16
hospitals. Of these, five subjects were excluded from the
study’s formal safety analysis: two received DTaP-IPV outside
the recommended age (Dose 1 given before 2 months of age),
two were of non-Korean ethnicity, and one subject received
vaccination in another country (United Kingdom). As such,
639 children were included in the vaccinated cohort for safety
analyses of which 342 (53.5%) were male. Demographic data
for children in this cohort are shown in Table 1.
Of the 639 children receiving at least one DTaP-IPV dose
within the PMS period, some subjects received more than one
vaccine dose; 302 (47.3%) received one dose; 121 (18.9%)
received two doses, and 216 subjects (33.8%) received three
doses (with a total of 1,192 separate vaccine doses administered
within this PMS). When accounting for overlap due to multiple
dosing, 576 children (90.1%) received at least one DTaP-IPV
dose as part of their primary vaccination series and 63 (9.9%)
received a booster dose. From a dosing schedule perspective,
the number of subjects receiving the DTaP-IPV primary vacci-
nation sequence was as follows; Dose 1, n = 367 (57.4% of the
overall cohort); Dose 2, n = 373 (58.4%); and Dose 3, n = 389
(60.9%). Of these, 367 (57.4%) received their first dose (as Dose
1) aged between 8–16 weeks of age, 110 (17.2%) received their
first dose (as Dose 2) between 16–24 weeks of age, and 99
(15.5%) received their first dose (as Dose 3) aged between
24 weeks to 48 months. Of those receiving a booster dose, 40
(6.3%) received it when aged between 48–60 months and 23
(3.6%) were >60 months of age (Figure 1).
A history of vaccination within 30 days prior to DTaP-IPV
administration was reported for 242 subjects (37.9%), principally
for protection against hepatitis or rotavirus infection. When con-
sidering any concomitant vaccination (i.e., from 30 days before
the administration of DTaP-IPV until 30 days after the final
administration of DTaP-IPV), this was reported in 567 (88.7%)
subjects, principally Haemophilus influenzae type b, pneumococ-
cal, rotavirus and hepatitis vaccines (Supplementary Table 1).
Two hundred and fifty-six subjects (40.1%) had a history of
previous medical illness, including 114 children (17.8%) with
conditions arising in the perinatal period and 67 (10.5%) with
respiratory conditions. Illness at the time of vaccination was
reported in 148 subjects (23.2%), including respiratory condi-
tions in 44 subjects (6.9%), congenital malformations and chro-
mosomal abnormalities in 26 subjects (4.1%), and skin or
subcutaneous tissue disorders in 25 subjects (3.9%).
Concomitant medication was reported by 317 (49.6%) subjects
during the 30-day period following vaccination; cough or cold
preparations by 168 (26.3%), allergy medications by 156 (24.4%),
analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs)
by 135 (21.1%), and anti-infective agents (antibiotics, antifungals
or antivirals) by 92 subjects (14.4%) (Supplementary Table 1).
Safety
All AEs, ADRs, SAEs and serious ADRs were reported after each
dose. Overall during the 30-day post-vaccination follow-up per-
iod, AEs were reported in 289 subjects (45.2%), who experienced
a total of 587 AEs (Table 2). For children receiving DTaP-IPV in
the primary vaccination series, the relative number of subjects in
whom an AE was reported after each dose was similar: dose 1
(n = 97, 26.4%), dose 2 (n = 113, 30.3%), and dose 3 (n = 113,
29.0%). An AE was reported in 31 children (49.2%) receiving
a booster dose (Supplementary Table 2). Most AEs were non-
serious (553/587, 94.2% of all AEs), occurring in 263 subjects. Of
these, 487/553 (88.1%) were considered by the investigator to be
ofmild intensity with 59/553 (10.7%)moderate and 7/553 (1.3%)
severe. Of these non-serious AEs, six required attendance at the
Emergency department, and 289 were treated by medical staff;
no other AEs required formal medical care.
Table 1. Study population and vaccine doses received.
Parameter Total N = 639
Male 342 (53.5%)
Body weight, kg
Median (range) 6.3 (1.5–43.8)
Age when subjects received primary vaccine
dose within the PMS
8–16 weeks 367 (57.4%)
>16–24 weeks 110 (17.2%)
>24 weeks – <48 months 99 (15.5%)
Age when subjects received the booster dose
within the PMS
48–60 months 40 (6.3%)
>60 months 23 (3.6%)
Number of vaccine doses received
1 302 (47.3%)
2 121 (18.9%)
3 216 (33.8%)
Receiving primary vaccination dose 576 (90.1%)
Dose 1 367 (57.4%)
Dose 2 373 (58.4%)
Dose 3 389 (60.9%)
Receiving booster vaccination dose 63 (9.9%)
All data are presented as number of subjects (%) except where otherwise stated
N, total vaccinated cohort; PMS, post-marketing surveillance
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Of the total 587 AEs, 465/587 (79.2%) were considered by
the investigators as “unlikely” to be related to the study
vaccine, and 122/587 AEs (20.8%) occurring in 83 subjects
(13.0%) were considered an ADR (i.e., any AE whose causality
due to the study vaccine could not be ruled out). Ten AEs
(1.7%) were considered by the investigators as “Certainly”
related to the vaccine, with 68 AEs (11.6%) considered
“Possibly” related to the vaccine, 36 AEs (6.1%) considered
“Probable/Likely” related to the vaccine, 4 AEs (0.7%)
considered “Conditional/Unclassified” and 4 AEs (0.7%) con-
sidered “Unassessable/Unclassifiable”.
The most frequently reported AEs and ADRs are shown in
Table 2 (and Supplementary Table 2). Fever was the most
commonly reported AE, with 87/587 cases (14.8% of all AEs)
occurring in 76 subjects (11.9% of the study population).
Fever was also the most commonly reported ADR, with 59/
122 cases (48.4%) occurring in 54 subjects (8.5% of the study
population). Injection-site swelling, erythema or pain or other
Enrolled (n=644)
Excluded (n=5)
• Non-Korean ethnicity (n=2)
• Vaccinated out with licensed use (n=2)
• Vaccinated outside Korea (n=1)
Included (n=639)
Number of DTaP-IPV doses received
• One dose  (n=302)
• Two doses (n=121)
• Three doses (n=216)
Dose 3 (n=389) Booster Dose (n=63)Dose 1 (n=367) Dose 2 (n=373)
Follow-up
Day 0
• Medical and vaccination history
Day 0 to day 30 (after each dose)
• AE monitoring
Day 0  to 30 days after last vaccine dose
• SAE monitoring
Figure 1. Study flow.
AE, adverse event; SAE, serious adverse event
Table 2. Adverse events (AEs) and adverse drug reactions (ADRs) over the PMS period.
N = 639 (total number of vaccinations = 1,192)
Adverse Event (AE) Adverse drug reaction (ADR)
AE
Subjects
n (%, 95% CI)
AE
n (%) ADR
Subjects
n (%, 95% CI)
ADR
n (%)
At least one AE 289 (45.2; 41.3–49.2) 587 At least one ADR 83 (13.0; 10.5–15.9) 122
Fever 76 (11.9; 9.5–14.7) 87 (14.8%) Fever 54 (8.5; 6.4–10.9) 59 (48.4%)
Common cold 49 (7.7; 5.7–10.0) 55 (9.4%) Irritability 15 (2.3; 1.3–3.8) 16 (13.1%)
URTI 46 (7.2; 5.3–9.5) 57 (9.7%) Injection-site swelling 8 (1.3; 0.5–2.5) 8 (6.6%)
Coughing 24 (3.8; 2.4–5.5) 24 (4.1%) Injection-site erythema 7 (1.1; 0.4–2.2) 7 (5.7%)
Irritability 23 (3.6; 2.3–5.4) 25 (4.3%) Injection-site pain 2 (0.3; 0.0–1.1) 2 (1.6%)
Gastroenteritis 23 (3.6; 2.3–5.4) 26 (4.4%) Fatigue 2 (0.3; 0.1–1.1) 2 (1.6%)
Rhinorrhoea 23 (3.6; 2.3–5.4) 24 (4.1%) Vomiting 2 (0.3; 0.1–1.1) 2 (1.6%)
Bronchitis 23 (3.6; 2.3–5.4) 23 (3.9%) Rash 2 (0.3; 0.1–1.1) 2 (1.6%)
Bronchiolitis 22 (3.4; 2.3–5.4) 23 (3.9%) Erythema 2 (0.3; 0.1–1.1) 2 (1.6%)
Diarrhea 17 (2.7; 1.6–4.2) 19 (3.2%) Injection-site induration 2 (0.3; 0.0–1.1) 2 (1.6%)
Injection-site reaction 1 (0.2; 0.0–0.9) 1 (0.8%)
Kawasaki disease 1 (0.2; 0.0–0.9) 2 (1.6%)
N = total number of infants receiving study vaccine overall (any dose and by specific dose); subject n (%): number (percentage) of subjects with an AE or ADR; AE
n (%): number of AEs and (%); ADR n (%): number of ADRs and (%); AE, adverse event; URTI, upper respiratory tract infection.
All % are based on the number of subjects or AEs or ADRs for the respective period.
Subjects may experience more than one AE category.
95% CI: 95% confidence interval; ADR, adverse drug reaction; AE, adverse event; PMS, post-marketing surveillance; URTI, upper respiratory tract infection.
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local reaction was relatively uncommon, with a total of 20
injection-site ADRs being reported (16.4% of all ADRs)
occurring in 16/639 subjects (2.5% of the study population).
Of these; 11 injection-site ADRs occurred in 10/576 subjects
(1.7%) who received the vaccine as part of the primary vacci-
nation schedule and nine reactions occurred in 6/63 subjects
(9.5%) who received a booster dose.
Of the total AEs reported, 350/587 (59.6%) were consid-
ered as unexpected AEs reported in 210/639 subjects (32.9%
of the study population). Respiratory or gastrointestinal dis-
orders were most commonly reported; common cold in 49/
639 subjects (7.7%), upper respiratory tract infection (URTI)
in 46 (7.2%) and gastroenteritis in 23 subjects (3.6%). A total
of 17 unexpected AEs occurring in 12 subjects (1.9%) were
considered unexpected ADRs (13.9% of all ADRs). Of these,
only fatigue was reported in more than one subject (Table 3
and Supplementary Table 3).
Of the 587 AEs reported, 34 (5.8%) were categorized as
SAEs, reported in 26 subjects (4.1% of the overall study
population). The most commonly reported SAEs were eight
cases of bronchiolitis in eight subjects (1.3%), five cases of
gastroenteritis in five subjects (0.8%), four cases of pneumonia
in four subjects (0.6%), and colitis or urinary tract disorders,
each reported in three subjects (0.5%) (Table 4 and
Supplementary Table 4). There were no deaths during this
surveillance period.
Most SAEs were considered unrelated to the study vaccine,
although in two cases a causal association could not be ruled
out, and so these were considered serious ADRs. They included
the occurrence of Kawasaki disease in a male infant, 12 days
after the first vaccine dose (as Dose 1), which required hospi-
talization and treatment with immunoglobulin and aspirin.
This subject made a complete recovery after 5 days, and this
event was considered by the investigator as “unassessable/
unclassifiable” in association with the vaccine. In another sub-
ject, fever requiring hospitalization occurred following receipt
of a third vaccine dose, which resolved within 48 hours; this
was considered as “possibly” related to the vaccine. There were
no marked differences in frequency of events (i.e., any AEs or
ADRs, unexpected AEs or unexpected ADRs, or SAEs or
serious ADRs) after any specific vaccine dose.
Of the five subjects excluded from the safety analysis
cohort (due to vaccination outside the licensed indication
and use), five AEs were reported in three subjects (fever,
vomiting, loose stools, bronchitis and tonsillitis). Of these,
two were considered SAEs (bronchitis and tonsillitis) reported
in the same subject. None of these AEs/SAEs were considered
related to the study vaccine.
Subject characteristics and overall adverse events
We evaluated the effects of subject-specific characteristics on
the incidence of AEs, including that of specific populations as
required by MFDS in Korea.17,20 In the overall cohort, 4/639
subjects had renal impairment, of which three subjects experi-
enced a total of six AEs. One subject with hydronephrosis
experienced four AEs (fever, pneumonia, coughing and otitis
media) which required hospitalization, none were considered
related to the vaccine. Two subjects each experienced a single
AE. Of these, one subject developed fever (requiring hospita-
lization) so it was considered an SAE, and was categorized as
“probably” related to the vaccine, and recorded as
a serious ADR.
There were no significant differences by gender, current or
past medical history or by previous or concomitant vaccination
and reporting of number of subjects with AEs (Table 5).
However, AEs were significantly more frequent in children tak-
ing concomitant medication (74.1%) compared to those who
were not (16.8%; p < 0.0001). AEs were also more frequent in
children receiving more than one vaccine dose; 38.7% of chil-
dren receiving only one dose experienced an AE, while AEs were
reported in 53.7% of those receiving two doses and in 49.5% of
those receiving three doses (p = 0.006). When evaluating relative
frequency of AEs as a proportion of all AEs by number of doses
Table 3. Unexpected adverse events and adverse drug reactions over the PMS period.
N = 639 (total number of vaccinations = 1,192)
Adverse Event (AE) Adverse drug reaction (ADR)
AE
Subjects
n (%, 95% CI)
AE
n (%) ADR
Subjects
n (%, 95% CI)
ADR
n (%)
At least one unexpected AE 210 (32.9; 29.2–36.7) 350 At least one unexpected ADR 12 (1.9; 1.0–3.3) 17
Common cold 49 (7.7; 5.7–10.0) 55 (15.7%) Fatigue 2 (0.3; 0.0–1.1) 2 (11.8%)
URTI 46 (7.2; 5.3–9.5) 57 (16.3%) Kawasaki disease 1 (0.2; 0.0–0.9) 2 (11.8%)
Gastroenteritis 23 (3.6; 2.3–5.4) 26 (7.4%) Dizziness 1 (0.2; 0.0–0.9) 1 (5.9%)
Rhinorrea 23 (3.6; 2.3–5.4) 24 (6.9%) URTI 1 (0.2; 0.0–0.9) 1 (5.9%)
Bronchiolitis 22 (3.4; 2.2–5.2) 23 (6.6%) Bronchiolitis 1 (0.2; 0.0–0.9) 1 (5.9%)
Otitis media 15 (2.4; 1.3–3.8) 16 (4.6%) Laryngitis 1 (0.2; 0.0–0.9) 1 (5.9%)
Pneumonia 10 (1.6; 0.8–2.9) 10 (2.9%) Tonsillitis 1 (0.2; 0.0–0.9) 1 (5.9%)
Pharyngitis 1 (0.2; 0.0–0.9) 1 (5.9%)
Constipation 1 (0.2; 0.0–0.9) 1 (5.9%)
Flank Pain 1 (0.2; 0.0–0.9) 1 (5.9%)
Conjunctivitis 1 (0.2; 0.0–0.9) 1 (5.9%)
Insomnia 1 (0.2; 0.0–0.9) 1 (5.9%)
Sleep disorder 1 (0.2; 0.0–0.9) 1 (5.9%)
Feeding disorder in child 1 (0.2; 0.0–0.9) 1 (5.9%)
Viral infection 1 (0.2; 0.0–0.9) 1 (5.9%)
N = total number of infants receiving study vaccine overall (any dose and by specific dose); subject n (%): number (percentage) of subjects with an AE or ADR; AE
n (%): number of AEs and (%); ADR n (%): number of ADRs and (%).
All % are based on the number of subjects or AEs or ADRs for the respective period.
Subjects may experience more than one AE category.
95% CI: 95% confidence interval; ADR, adverse drug reaction; AE, adverse event; PMS, post-marketing surveillance; URTI, upper respiratory tract infection.
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Table 4. Serious adverse events and serious adverse drug reactions over the PMS period.
N = 639 (total number of vaccinations = 1,192)
Serious Adverse Event (SAE) Serious Adverse drug reaction (ADR)
SAE
Subjects
n (%, 95% CI)
SAE
n (%) Serious ADR
Subjects
n (%, 95% CI)
Serious ADR
n (%)
At least one SAE 26 (4.1; 2.7–5.9) 34 At least one serious ADR 2 (0.3; 0.0–1.1) 2
Bronchiolitis 8 (1.3; 0.5–2.5) 8 (23.5%) Fever 1 (0.2; 0.0–0.9) 1 (50.0%)
Gastrointestinal infection 7 (1.1; 0.4–2.2) 9 (26.5%) Kawasaki disease 1 (0.2; 0.0–0.9) 1 (50.0%)
Gastroenteritis 5 (0.8; 0.3–1.8) 5 (14.7%)
Pneumonia 4 (0.6; 0.2–1.6) 4 (11.8%)
Colitis 3 (0.5; 0.1–1.4) 3 (8.8%)
URTI 1 (0.2; 0.0–0.9) 1 (2.9%)
Common cold 1 (0.2; 0.0–0.9) 1 (2.9%)
Bronchitis 1 (0.2; 0.0–0.9) 1 (2.9%)
Pharyngotonsillitis 1 (0.2; 0.0–0.9) 1 (2.9%)
Otitis media 1 (0.2; 0.0–0.9) 1 (2.9%)
Viral infection 1 (0.2; 0.0–0.9) 1 (2.9%)
Sepsis 1 (0.2; 0.0–0.9) 1 (2.9%)
Fever 1 (0.2; 0.0–0.9) 1 (2.9%)
Urinary tract infection 1 (0.2; 0.0–0.9) 1 (2.9%)
Cystitis 1 (0.2; 0.0–0.9) 1 (2.9%)
Pyelonephritis 1 (0.2; 0.0–0.9) 1 (2.9%)
Kawasaki disease 1 (0.2; 0.0–0.9) 1 (2.9%)
Cervical lymphadenitis 1 (0.2; 0.0–0.9) 1 (2.9%)
N = total number of infants receiving study vaccine overall (any dose and by specific dose); subject n (%): number (percentage) of subjects with an SAE or serious
ADR; SAE n (%): number of SAEs and (%); Serious ADR n (%): number of Serious ADRs and (%).
All % are based on number of subjects or SAEs or Serious ADRs for the respective period.
Subjects may experience more than one SAE category.
95% CI: 95% confidence interval; ADR, adverse drug reaction; PMS, post-marketing surveillance; SAE, serious adverse event; URTI, upper respiratory tract infection.
Table 5. Subject characteristics and incidence of adverse events (AEs).
Characteristic
Adverse Event
n
Subjects with Adverse Event
n (%, 95% CI) P-Value
Renal impairment
Yes (N = 4) 6 3 (75.0; 19.4–99.4) 0.333a
No (N = 635) 581 286 (45.0; 41.1–49.0)
Gender
Male (N = 342) 314 162 (47.4; 42.0–52.8) 0.243
Female (N = 297) 273 127 (42.8; 37.1–48.6)
Age
Primary vaccination 0.080
8–16 weeks (N = 367) 325 152 (41.4; 36.3–46.7)
>16–24 weeks (N = 110) 124 58 (52.7; 43.0–62.3)
>24 weeks – <48 months (N = 99) 80 48 (48.5; 38.3–58.8)
Booster 0.225
48–60 months (N = 40) 33 22 (55.0; 38.5–70.7)
>60 months (N = 23) 25 9 (39.1; 19.7–61.5)
Previous medical condition
Yes (N = 256) 237 115 (44.9; 38.7–51.2) 0.899
No (N = 383) 350 174 (45.4; 40.4–50.6)
Current medical condition
Yes (N = 148) 152 65 (43.9; 35.8–52.3) 0.715
No (N = 491) 435 224 (45.6; 41.2–50.1)
Previous vaccination
Yes (N = 242) 201 98 (40.5; 34.3–47.0) 0.057
No (N = 396) 386 191 (48.2; 43.2–53.3)
Concomitant vaccination
Yes (N = 567) 527 254 (44.8; 40.7–49.0) 0.540
No (N = 72) 60 35 (48.6; 36.7–60.7)
Concomitant medication
Yes (N = 317) 490 235 (74.1; 68.9–78.9) <0.0001
No (N = 322) 97 54 (16.8; 12.9–21.3)
Number of vaccine doses received
1 (N = 302) 200 117 (38.7; 33.2–44.5) 0.006
2 (N = 121) 158 65 (53.7; 44.4–62.8)
3 (N = 216) 229 107 (49.5; 42.7–56.4)
a P-values calculated using Fisher exact test
Adverse event n (%): number of AEs; Subjects with Adverse event n (%): number (percentage) of subjects with an AE with 95% confidence intervals.
Subjects may experience more than one AE category.
95% CI: 95% confidence interval; AE, adverse event.
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received; 200/587 AEs were reported (34.1%) in those receiving
one dose, 158/587 (26.9%) in children receiving two doses and
229/587 (39.0%) in those receiving three doses.
Discussion
Immunization against diphtheria, tetanus, pertussis and polio
are key aspects of childhood immunization strategy in Korea.4
As such, real-world data from vaccine use in clinical practice
regarding safety are essential to inform and improve vaccine
use in eligible children.
This PMS assessed the safety of the DTaP-IPV vaccine in
639 Korean children when used within routine childhood
immunization schedules between 2010 and 2016. We found
that the vaccine was well-tolerated with no apparent safety
concerns. Figure 2 presents a summary of the context, out-
comes, and the impact of this study for health care providers.
AEs were reported in 45.2% of children receiving the study
vaccine, although most were mild in intensity. As may be
expected, more AEs were reported in those subjects receiving
more than one dose of DTaP-IPV. Receiving other vaccines
within 30 days of the study vaccine did not influence the
frequency of AEs.
The most common expected AE was fever, occurring in
11.9% of subjects, and which accounted for 14.8% of all AEs
and 48.4% of all ADRs. This rate is similar to that reported in
the pre-licensure RCT investigating immunogenicity and
safety in Korean infants (fever ≥37.5°C reported in 11.6% of
children8) but slightly higher than data from RCTs in non-
Korean populations (US, Europe, Australia) that reported
rates of fever ranging from 6.1% to 9.6%.6,14 Local injection-
site reactions were relatively uncommon, with 20 such AEs
occurring in 16 subjects (2.5%), most of which were of mild
intensity. This is substantially lower than that reported in
previous studies in Korean infants (where the proportion of
infants with reactions ranged from 17.4% to 32.4%)8 and is
lower than that reported in previous studies in non-Korean
populations.6,14
The majority of all AEs reported (59.6%) were considered
as unexpected AEs, representing signs/symptoms not
described in the Korean PI. Of these, the most frequently
reported were respiratory conditions and gastrointestinal
infections. While most were considered not vaccine-related,
17 unexpected AEs were considered ADRs accounting for
14% of all ADRs. Most ADRs were isolated cases, although
continued monitoring of unexpected ADRs will be important
to determine whether these findings are of wider clinical
importance.
Over this surveillance period, SAEs were reported in
4.1% of subjects. Most SAEs were unexpected events
(bronchiolitis, pneumonia, gastroenteritis or colitis and
urinary tract disorders); again, most were assessed as non-
vaccine related. Two SAEs were considered serious ADRs
i.e., for which the causal relationship to the vaccine could
not be ruled out. Both cases required hospitalization,
although both resolved quickly. In one case, complete
recovery from fever was made within 24 hours without
specialized treatment. In the second SAE case, that of
Kawasaki disease occurring after receiving the first DTaP-
IPV dose, standard treatment (immunoglobulin and aspirin)
led to recovery within five days. While the investigator
reported this event as “unassessable/unclassifiable” in asso-
ciation with the study vaccine administration (and this
infant also received vaccination against rotavirus infection
with a pentavalent vaccine), it should be recognized that no
clear causal association between vaccination with DTaP-IPV
(or any other vaccine) and Kawasaki disease has been
found.21,22 Furthermore Korea has the second highest
Focus on the Patient 
What is new? 
What is the impact? 
What is the context? 
Globally, diphtheria, tetanus, pertussis (or whooping cough) and polio cause significant morbidity and mortality particularly 
amongst children. In Korea vaccination against these diseases is included in the National Immunization Program and is 
recommended for children. Infanrix-IPV (GSK, Belgium), a combined diphtheria, tetanus, acellular pertussis, and inactivated 
poliovirus vaccine (DTaP-IPV), has been available in Korea since 2012. Combination vaccines simplify vaccination schedules and 
may aid uptake therefore helping to prevent these diseases. 
In this study we evaluated the safety of DTaP-IPV administered to children in routine immunization schedules in Korea 
between 2010 and 2016. Adverse events (AEs) were reported in less than half of those receiving DTaP-IPV. Most AEs were mild 
in intensity and unlikely to be related to the study vaccine, all were resolved. Overall, we found that DTaP-IPV is well tolerated 
in Korean children and its safety profile was as expected based on data from other studies. 
Our findings show that infant immunization with DTaP-IPV in Korean children is a well-tolerated strategy in vaccinating 
against childhood diseases such as diphtheria, tetanus, whooping cough, and polio in real world clinical practice. 
Figure 2. Focus on the patient.
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incidence of Kawasaki disease in the world (after Japan).23
In this case, the infant subsequently received a second dose
of DTaP-IPV without any AEs.
Our study has limitations. This was an observational PMS
collecting only safety data within routine clinical practice, and
the absence of any comparative control group dictates that
these data should be interpreted accordingly. Furthermore,
our sample size may not be sufficient to detect rare AEs,
while comparisons between specific groups may have been
influenced by confounders. Nevertheless, our data contribute
to existing real-world evidence regarding the acceptable safety
of DTaP-IPV in young children.
Conclusions
In summary, in this PMS conducted over six years in Korean
children, we found that DTaP-IPV was well tolerated, with an
acceptable safety profile.
Methods
Study design and study population
This was a multicenter PMS conducted between June 2010
and June 2016 at 16 hospitals in Korea (NCT01568060).
Eligible subjects were children of Korean ethnicity aged
between 2 and 83 months who had received at least one
dose of DTaP-IPV as part of their routine childhood immu-
nizations (either as part of the primary vaccination schedule
or as a subsequent booster dose) in accordance with the
Korean PI.6 The study was conducted in accordance with
MFDS regulatory requirements and the local rules and reg-
ulations recruiting a minimum of 600 subjects.17,20
Ethics statement
The study was approved by the independent ethics committee
at each participating center. Parents or guardians of subjects
provided written informed consent for data collection and
analysis before study enrollment.
DTAP-IPV vaccine
Infanrix-IPV, manufactured by GSK, Belgium, comes in a sterile
suspension in a single-dose prefilled syringe. Each 0.5 mL vac-
cine dose contains antigens against the four target pathogens;
a minimum of 30 international units (IU) of diphtheria toxoid,
40 IU of tetanus toxoid, three purified antigens of Bordetella
pertussis (25 μg of pertussis toxoid [PT], 25 μg of filamentous
haemagglutinin [FHA] and 8 μg of pertactin [PRN], each
adsorbed onto aluminium salt), and three distinct poliovirus
antigens; 40 D-antigen units of type 1 poliovirus (Mahoney
strain), 8 D-antigen units of type 2 poliovirus (MEF-1 strain)
and 32 D-antigen units of type 3 poliovirus (Saukett strain). The
vaccine is administered intramuscularly in the thigh (infants
≤2 years) or deltoid (in older children).
Data collection, safety assessments and AE, ADR and SAE
definitions
For all subjects, demographic data, past and current medical
history, vaccination history, and data regarding use of con-
comitant vaccinations/medication were collected at the time
of the first vaccine dose within the PMS and updated at any
subsequent vaccine dose. Concomitant vaccinations included
any other vaccinations administered from 30 days before the
administration of the first dose of DTaP-IPV within the PMS
until 30 days after the final administration of DTaP-IPV.
Concomitant medication was defined as any medication
(excluding vitamins) given within a 30-day period prior to
or following administration of each vaccine dose (including
medications administered to treat an AE or given prophylac-
tically to prevent any vaccine reaction). At all visits the sub-
jects’ axillary, rectal, oral or tympanic temperature was
measured prior to vaccination to ensure administration in
the absence of fever (oral, axillary or tympanic temperature
≥37.5°C [99.5°F], or rectal temperature ≥38.0°C [100.4°F]).
Subjects were followed up for a period of 30 days after
receiving any DTaP-IPV dose. For each subject, the occur-
rence of any AEs was recorded by the parent/guardian in
a diary card and returned to the investigators who recorded
all safety information in case report forms. An AE was defined
as any untoward medical occurrence, temporally associated
with vaccine administration and coded using the World
Health Organization Adverse Reactions Terminology (WHO-
ART 092 version). The intensity of AEs was recorded as: mild
(easily tolerated by the subject, causing minimal discomfort
and not interfering with everyday activities), moderate (suffi-
ciently discomforting to interfere with normal everyday activ-
ities; fever >38 and ≤39°C) or severe (prevented normal,
everyday activities; fever >39°C).
An SAE was defined as any untoward medical occurrence
that either resulted in death, was life-threatening, required
hospitalization or prolongation of existing hospitalization, or
resulted in disability or incapacity. SAEs were recorded
throughout the study (i.e., from receiving the first dose of the
study vaccine until 30 days after receiving the last vaccine dose).
SAEs were identified by study investigators on the basis of diary
cards, case report forms and hospital records (with reporting in
accordance with the national PMS SAE reporting system). All
subjects were followed up until resolution of the AE/SAE or lost
to follow-up. AEs (or SAEs) listed in the Korean PI of the study
vaccine were categorized as ‘expected’, and those not listed were
categorized as ‘unexpected’. Adverse drug reactions (ADRs)
were defined as any AE/SAE whose causality to DTaP-IPV
could not be ruled out. Causality was categorized as certain,
probable/likely, possible, unlikely, conditional/unclassified and
unassessable/unclassifiable using criteria based on MFDS gui-
dance (modified from the World Health Organization-The
Uppsala Monitoring Centre [WHO-UMC] causality scale).20,24
Data analysis
This was an observational safety study using a pre-defined
sample size (≥600) in line with MFDS regulatory requirements,
and as such no formal sample size calculation was performed.
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All data were anonymized and analyses were performed on the
vaccinated cohort comprising all subjects eligible for study
inclusion who received at least one vaccine dose. The number
of subjects experiencing an AE, SAE, or ADR, and the number
experiencing expected or unexpected events in each category
were analyzed; incidence rates and exact 95% confidence inter-
vals (CI) were then calculated, for the overall cohort and for
those receiving specific doses (Doses 1, 2, and 3, or booster
dose). The overall incidence of AEs was also stratified by specific
factors (gender, medical conditions, concomitant medications,
concomitant vaccination, and number of doses received) and
comparisons of incidence between groups performed using the
Chi2 test or Fisher exact test. No formal statistical adjustment
for multiple comparisons was applied. Statistical analyses were
performed using SAS software (version 9.4; SAS Institute, Inc.,
NC, USA).
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